From the Journals

Obesity hope as neuropeptide Y blocker turns white fat to brown


 

Neuropeptide Y receptor blockage: A treatment for many ills?

Previously, Dr. Herzog and colleagues found that blockade of the neuropeptide Y1 receptor also increases bone mass in mice.

“It’s a modest effect, but there’s nothing out there at the moment that really improves bone mass. If you can stop osteoporosis, that’s a benefit on its own,” he said.

Now they hope to study BIBO’s vasodilatory properties as a potential treatment for hypertension, if they get the funding.

Dr. Herzog is hopeful, as obesity, osteoporosis, and hypertension are all chronic conditions. “Having one drug that benefits them all would surely be of interest to clinicians and drug companies,” he observed.

Dr. Yan and Dr. Herzog have reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Severe obesity persists, takes high cardiovascular toll
Journal of Clinical Outcomes Management
AHA statement on obesity emphasizes abdominal fat, AFib
Journal of Clinical Outcomes Management
Being overweight ups risk of severe COVID-19 in hospital
Journal of Clinical Outcomes Management
Weight-related COVID-19 severity starts in normal BMI range, especially in young
Journal of Clinical Outcomes Management
Exercise plus liraglutide better for maintaining weight loss than either strategy alone
Journal of Clinical Outcomes Management
A simple new definition for ‘metabolically healthy obesity’?
Journal of Clinical Outcomes Management
Possible obesity effect detected in cancer death rates
Journal of Clinical Outcomes Management
Two treatments show early promise for hypothalamic obesity
Journal of Clinical Outcomes Management
High teen BMI linked to stroke risk in young adulthood
Journal of Clinical Outcomes Management
‘Inflammasomes’ may play a role in obesity-related CRC
Journal of Clinical Outcomes Management